Education Hub
Your central resource for evidence-based content in metabolic, cardiovascular, and renal medicine.
Core Topics
Landmark Trials
Educational summaries and commentary on pivotal clinical trials...
Coming Soon - New landmark trial videos will be added here shortly.
Number of videos found or no matching video
Heading 1
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.
Heading 1
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.
Heading 1
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.
Heading 1
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.
Heading 1
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.
Heading 1
I'm a paragraph. Click here to add your own text and edit me. It's easy.
I'm a paragraph. Click here to add your own text and edit me. It's easy.
Landmark Trials
Contemporary approaches to diabetes management, complications, and therapeutic advances.
Diabetes
Contemporary approaches to diabetes management, complications, and therapeutic advances.
Mounjaro for Better Sleep?
14:33
In this video the @GoggleDocs preview the upcoming American Diabetes Association annual conference, taking place in June 2024, in Orlando, Florida.
WEIGHT LOSS... and the diabetes crisis
13:03
We review the latest issues for Ozempic, Trulicity and Tresiba for patients with Diabetes.
2022: Every Diabetes Guideline Update... in 30 minutes!
35:18
@GoggleDocs give their overview of the last year in Diabetes Guideline updates; NICE, ADA/EASD and KDIGO.
ACHIEVE-1: Oral GLP-1 in T2D – ADA 2025 Preview
1:56
Dr Patrick Holmes walks through ACHIEVE-1, a key ADA 2025 trial on orforglipron – the first oral non-peptide GLP-1RA for type 2 diabetes.
The GLP-1 Story... (a GoggleDocs Podcast)
58:36
In this GoggleDocs podcast we discuss the journey of GLP-1 agonists, from Gila Monster Saliva to Ozempic, Wegovy and Mounjaro.
GoggleDocs Pod # 4 | Underserved Communities in Diabetes
45:52
The united colours of Diabetes"... each person living with diabetes has their own unique physical, psychological and social characteristics.
Obesity
Weight management, metabolic health, and the evolving treatment landscape for obesity.
Muscle Matters: BELIEVE & COURAGE at ADA 2025
2:08
Dr Amar Puttanna covers two important ADA 2025 trials that zoom in on muscle preservation during GLP-1-driven weight loss.
Breaking News top-line results of the TRIUMPH-4 study (retatrutide)
2:20
Retatrutide delivers AGAIN!!! Experimental weight-loss treatment retatrutide tested in a phase 3 randomised control trial in Overweight/Obese adults with osteoarthritic knee pain.
Ozempic... The Good, the Bad and the Ugly
5:13
Dr Patrick Holmes from @GoggleDocs brings you a 2024 update on Semaglutide (aka Ozempic, Wegovy, Rybelsus)... from the latest scientific evidence to the growing pains.
Wegovy, Ozempic, Rybelsus: a 2-minute summary
2:07
Dr Patrick Holmes brings us up to speed with the molecule that has taken the world of diabetes and bariatric medicine by storm
Breaking News in Obesity: STEP1 (w Dr Sarah Davies)
18:42
Patrick and Amrit are joined by fellow Primary Care GP, Dr Sarah Davies, to discuss the recently published STEP 1 trial.
Cardiovascular and Kidney Conditions
Heart failure, chronic kidney disease, atherosclerotic cardiovascular disease, lipid disorders, and other conditions in metabolic medicine.
Cafés, canals and cardiology. ESC 2023 Preview
19:16
We preview the European Society of Cardiology's Annual Congress, in Amsterdam (25-28 August 2023). Focusing on the latest with Semaglutide in Heart Failure.
Breaking News: SGLT2i in ACUTE Heart Failure
3:44
This bite-sized video is a summary of the recent EMPULSE study, that investigated the use of Empagliflozin in people admitted to hospital with acute heart failure.
The Chronic Kidney Disease Playbook 2024
11:18
Chronic Kidney Disease affects up to 1 billion people worldwide. With complications including reduced life expectancy, cardiovascular disease and kidney failure.